Sentences with phrase «cell lung cancer model»

Navitoclax Enhances the Efficacy of Taxanes in Non — Small Cell Lung Cancer Models.

Not exact matches

In the Cell study, Dr. Massagué, with Fellow Manuel Valiente, PhD, and other team members, found that in mouse models of breast and lung cancer — two tumor types that often spread to the brain — many cancer cells that enter the brain are killed by astrocytes.

«Our study results suggest a new drug cocktail that is effective in both human lung cancer cell lines and fly models,» says Cagan.

To test this idea, the researchers utilized two mouse models of human breast cancer metastasis and found dormant disseminated tumor cells residing upon the membrane microvasculature of lung, bone marrow and brain tissue.

One postdoc presents data on her efforts to develop an organoid model for small - cell lung cancer; another reports progress on culturing hormone - secreting organoids from human gut tissue.

To determine whether endothelial cells — the cells that line the interior surface of blood vessels — directly influence breast cancer cell growth, they then created unique organotypic models of lung and bone marrow microvascular niches, in which endothelial cells formed blood vessel - like structures in culture as they would in the original organ.

The study, called «Molecular Determinants of Drug - Specific Sensitivity for Epidermal Growth Factor Receptor (EGFR) Exon 19 and 20 Mutants in Non-Small Cell Lung Cancer,» and published online in the journal Oncotarget, demonstrates how computer modeling of EGFR mutations found in lung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patieLung Cancer,» and published online in the journal Oncotarget, demonstrates how computer modeling of EGFR mutations found in lung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patCancer,» and published online in the journal Oncotarget, demonstrates how computer modeling of EGFR mutations found in lung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patielung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patcancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patients.

The Manchester researchers tested a new drug that targets one of these molecules, MCT1, in lung cancer cells and in mouse models.

The article, titled «Entinostat Neutralizes Myeloid Derived Suppressor Cells and Enhances the Antitumor Effect of PD - 1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma,» was published in Clinical Cancer Research and is available online.

We have developed pre-clinical models to identify genes, both in the tumour cells and in the microenvironment that regulate the spread of cancer to specific organs such as the liver, lungs and brain.

Verma has successfully developed lentiviral vector - mediated mouse models for glioblastoma, lung adenocarcinoma and small cell lung cancer (SCLC).

Patient - derived xenograft models of non-small cell lung cancer and their potential utility in personalized medicine.

Life tables were used to model five year survival for early stage non-small cell lung cancer and limited stage small cell lung cancer, using death rates for continuing smokers and quitters obtained from this review.

In project on BRAF - mutant melanoma and EGFR - mutant non-small cell lung cancer, we conceived a novel drug sensitivity metric, the DIP rate, that makes it possible to incorporate drug - induced proliferation rates in predictive models of response.

In small cell lung cancer, starting from bioinformatics analyses of large gene expression datasets, we clustered subsets of co-expressed gene modules, derived networks of transcription factors and simulated their dynamics using logic - based mathematical modeling.

Life table modelling on the basis of these data estimated 33 % five year survival in 65 year old patients with early stage non-small cell lung cancer who continued to smoke compared with 70 % in those who quit smoking.